Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Puma Biotechnology (PBYI) Equity Average (2017 - 2025)

Puma Biotechnology's Equity Average history spans 9 years, with the latest figure at $122.8 million for Q4 2025.

  • For Q4 2025, Equity Average rose 50.48% year-over-year to $122.8 million; the TTM value through Dec 2025 reached $122.8 million, up 50.48%, while the annual FY2025 figure was $111.2 million, 52.83% up from the prior year.
  • Equity Average reached $122.8 million in Q4 2025 per PBYI's latest filing, up from $110.0 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $122.8 million in Q4 2025 to a low of -$6.7 million in Q4 2021.
  • Average Equity Average over 5 years is $44.7 million, with a median of $31.3 million recorded in 2023.
  • Peak YoY movement for Equity Average: crashed 108.74% in 2021, then skyrocketed 909.9% in 2023.
  • A 5-year view of Equity Average shows it stood at -$6.7 million in 2021, then soared by 427.37% to $21.9 million in 2022, then soared by 110.64% to $46.1 million in 2023, then soared by 77.05% to $81.6 million in 2024, then surged by 50.48% to $122.8 million in 2025.
  • Per Business Quant, the three most recent readings for PBYI's Equity Average are $122.8 million (Q4 2025), $110.0 million (Q3 2025), and $100.9 million (Q2 2025).